AR095422A1 - Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina - Google Patents
Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexinaInfo
- Publication number
- AR095422A1 AR095422A1 ARP140100966A ARP140100966A AR095422A1 AR 095422 A1 AR095422 A1 AR 095422A1 AR P140100966 A ARP140100966 A AR P140100966A AR P140100966 A ARP140100966 A AR P140100966A AR 095422 A1 AR095422 A1 AR 095422A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- compounds
- pyrimidinyl
- halo
- triazolyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
La presente está dirigida a compuestos de la fórmula (1) en donde X es CR¹ o N; Y es CR² o N; Z es NH ó O; R¹ es alcoxi, triazolilo, oxazolilo, isoxazolilo, oxadiazolilo, o pirimidinilo; donde triazolilo, oxazolilo o pirimidinilo se sustituye opcionalmente hasta con dos sustituyentes seleccionados de halo o alquilo; R² es H, alquilo, o halo; R³ es H, alquilo, alcoxi, halo, triazolilo, oxazolilo, o pirimidinilo; R⁴ es alquilo; R⁵ es piridilo; benzoxazolilo; pirimidinilo; piridazinilo; quinoxalinilo; pirazinilo; o quinazolinilo; en donde el piridilo; benzoxazolilo; pirimidinilo; piridazinilo; quinoxalinilo; pirazinilo; o el quinazolinilo se sustituye, opcionalmente, con uno o dos sustituyentes independientemente seleccionados del grupo que consiste en alquilo, halo, o fenilo; y R⁶ es H o alquilo. Además, se describen los compuestos de la fórmula (1). Se refiere, además, a composiciones farmacéuticas que comprenden los compuestos de la fórmula (1). Los métodos para usar los compuestos de la presente se encuentran, además, dentro del alcance de la misma. Compuestos útiles ara tratar problemas de SNC.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780302P | 2013-03-13 | 2013-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR095422A1 true AR095422A1 (es) | 2015-10-14 |
Family
ID=50842314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100966A AR095422A1 (es) | 2013-03-13 | 2014-03-13 | Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina |
Country Status (9)
Country | Link |
---|---|
US (2) | US9115117B2 (es) |
EP (1) | EP2970207B1 (es) |
JP (1) | JP6275814B2 (es) |
CN (1) | CN105228995B (es) |
AR (1) | AR095422A1 (es) |
AU (2) | AU2014248763B2 (es) |
TW (1) | TW201444821A (es) |
UY (1) | UY35410A (es) |
WO (1) | WO2014165065A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
WO2016095204A1 (en) * | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor antagonists |
WO2017012502A1 (en) | 2015-07-17 | 2017-01-26 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
CA3005918C (en) | 2015-11-23 | 2023-10-17 | Sunshine Lake Pharma Co., Ltd. | Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof |
GB201601703D0 (en) * | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
CA3025260A1 (en) * | 2016-06-23 | 2017-12-28 | Lalit Kumar Sharma | Small molecule modulators of pantothenate kinases |
CN106045902A (zh) * | 2016-06-30 | 2016-10-26 | 苏州健雄职业技术学院 | 一种3‑溴‑6‑甲基‑2‑吡啶甲醛的制备方法 |
CA3041563C (en) | 2016-11-22 | 2023-10-31 | Dana-Farber Cancer Institute, Inc. | Pyrimidin-2-amine derivatives and pharmaceutical compositions thereof useful as inhibitors of cyclin-dependent kinase 12 (cdk12) |
TWI756418B (zh) | 2017-05-03 | 2022-03-01 | 瑞士商愛杜西亞製藥有限公司 | 2-([1,2,3]三唑-2-基)-苯甲酸衍生物之製備 |
JP2021508738A (ja) | 2017-12-27 | 2021-03-11 | セント ジュード チルドレンズ リサーチ ホスピタル,インコーポレイティド | Castorに関連する障害を治療する方法 |
BR112020012875A2 (pt) | 2017-12-27 | 2021-01-05 | St. Jude Children¿S Research Hospital, Inc. | Moduladores de pequenas moléculas das pantotenato quinases |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3674793A (en) | 1967-03-29 | 1972-07-04 | Sterling Drug Inc | 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones |
US6505492B2 (en) | 2001-04-11 | 2003-01-14 | Bethlehem Steel Corporation | Method and apparatus for forming deep-drawn articles |
US20040176361A1 (en) | 2001-05-23 | 2004-09-09 | Masakazu Fujio | Fused heterocyclic compound and medicinal use thereof |
AU2003202753A1 (en) | 2003-02-07 | 2004-08-30 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
EP1599483A1 (en) | 2003-02-21 | 2005-11-30 | Pharmacia & Upjohn Company LLC | Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo 2.2.1 heptane- 7-carboxylate, intermediates, and process to prepare and isolate them |
WO2007071358A1 (en) | 2005-12-20 | 2007-06-28 | Novartis Ag | Nicotinic acid derivatives as modulators of metabotropic glutamate receptors |
KR20090061041A (ko) | 2006-09-11 | 2009-06-15 | 노파르티스 아게 | 대사성 글루타메이트 수용체의 조절제로서의 니코틴산 유도체 |
EP2094685B1 (en) | 2006-12-01 | 2011-01-19 | Actelion Pharmaceuticals Ltd. | 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperdine derivatives as orexin receptor inhibitors |
CL2007003827A1 (es) | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
JP2010528007A (ja) | 2007-05-23 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | シクロプロピルピロリジンオレキシン受容体アンタゴニスト |
KR20100051814A (ko) | 2007-07-17 | 2010-05-18 | 브리스톨-마이어스 스큅 컴퍼니 | Gpr119 g 단백질-커플링된 수용체의 조절 방법 및 선택된 화합물 |
KR101204213B1 (ko) * | 2007-12-21 | 2012-11-26 | 에프. 호프만-라 로슈 아게 | 오렉신 수용체 길항제로서의 헤테로아릴 유도체 |
BRPI0908096A2 (pt) | 2008-02-21 | 2015-08-25 | Actelion Pharmaceuticals Ltd | Derivado de 2-aza-biciclo [2.2.1] heptano |
CA2722347A1 (en) * | 2008-04-30 | 2009-11-05 | Actelion Pharmaceuticals Ltd | Piperidine and pyrrolidine compounds |
EP2318404B1 (en) | 2008-07-16 | 2013-08-21 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
WO2010048012A1 (en) * | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
US8357700B2 (en) | 2008-10-21 | 2013-01-22 | Merck Sharp & Dohme Corp. | 2,3-disubstituted piperidine orexin receptor antagonists |
MX2011005800A (es) | 2008-12-02 | 2011-06-20 | Glaxo Group Ltd | Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos. |
AR076024A1 (es) | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
AU2010240871A1 (en) | 2009-04-24 | 2011-10-27 | Glaxo Group Limited | 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists |
JP5847087B2 (ja) | 2009-10-23 | 2016-01-20 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン受容体調節因子としての縮合複素環式化合物 |
PL2491038T3 (pl) | 2009-10-23 | 2016-10-31 | Dwupodstawione oktahydropirolo[3,4-c]pirole jako modulatory receptora oreksyny | |
WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
US9409918B2 (en) | 2009-10-29 | 2016-08-09 | Merck Sharp & Dohme Corp. | Bridged bicyclic piperidine derivatives and methods of use thereof |
WO2011066137A1 (en) | 2009-11-24 | 2011-06-03 | Schering Corporation | Substituted biaryl derivatives and methods of use thereof |
WO2011075415A1 (en) | 2009-12-14 | 2011-06-23 | Inspire Pharmaceuticals, Inc. | Bridged bicyclic rho kinase inhibitor compounds, composition and use |
WO2011087812A1 (en) | 2009-12-21 | 2011-07-21 | Vanderbilt University | Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
WO2011159657A1 (en) | 2010-06-18 | 2011-12-22 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and methods of use thereof |
WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
US9546152B2 (en) * | 2012-10-23 | 2017-01-17 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists |
RU2658006C2 (ru) | 2012-11-16 | 2018-06-19 | Мерк Шарп И Доум Корп. | Пуриновые ингибиторы человеческой фосфатидилинозит 3-киназы дельта |
TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途 |
EP3102569A1 (en) | 2014-02-06 | 2016-12-14 | AbbVie Inc. | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
-
2014
- 2014-03-11 TW TW103108298A patent/TW201444821A/zh unknown
- 2014-03-12 US US14/206,662 patent/US9115117B2/en active Active
- 2014-03-12 US US14/774,529 patent/US9611251B2/en active Active
- 2014-03-12 JP JP2016501463A patent/JP6275814B2/ja active Active
- 2014-03-12 WO PCT/US2014/024284 patent/WO2014165065A1/en active Application Filing
- 2014-03-12 EP EP14727268.6A patent/EP2970207B1/en active Active
- 2014-03-12 AU AU2014248763A patent/AU2014248763B2/en active Active
- 2014-03-12 CN CN201480027361.3A patent/CN105228995B/zh active Active
- 2014-03-13 UY UY0001035410A patent/UY35410A/es unknown
- 2014-03-13 AR ARP140100966A patent/AR095422A1/es unknown
-
2018
- 2018-09-12 AU AU2018229449A patent/AU2018229449A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2014248763B2 (en) | 2018-08-30 |
US9611251B2 (en) | 2017-04-04 |
US20140275095A1 (en) | 2014-09-18 |
CN105228995A (zh) | 2016-01-06 |
CN105228995B (zh) | 2018-12-25 |
JP6275814B2 (ja) | 2018-02-07 |
AU2014248763A1 (en) | 2015-08-27 |
US9115117B2 (en) | 2015-08-25 |
UY35410A (es) | 2014-09-30 |
AU2018229449A1 (en) | 2018-10-04 |
TW201444821A (zh) | 2014-12-01 |
WO2014165065A1 (en) | 2014-10-09 |
JP2016512534A (ja) | 2016-04-28 |
EP2970207A1 (en) | 2016-01-20 |
EP2970207B1 (en) | 2018-05-16 |
US20160046599A1 (en) | 2016-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR095422A1 (es) | Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina | |
AR123048A2 (es) | Moduladores de p2x7 | |
AR119454A2 (es) | COMPUESTOS ÚTILES COMO MODULADORES DE RORg, SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, COMPOSICIONES FARMACÉUTICAS Y DICHOS COMPUESTOS PARA USO COMO MEDICAMENTO | |
NI201500129A (es) | 7-azabiciclos sustituidos y su uso como moduladores del receptor de orexina. | |
ES2659397T3 (es) | 2-azabicíclicos sustituidos y su uso como moduladores receptores de orexinas | |
AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
NZ732812A (en) | Use of picolinamides and other compounds as fungicides | |
AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
AR097866A1 (es) | Derivados de 4-azaindol | |
CR20150661A (es) | Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas | |
AR092266A1 (es) | Inhibidores de ddr2 para el tratamiento de osteoartritis | |
AR088320A1 (es) | Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt | |
CR20160030A (es) | Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
AR095570A1 (es) | Derivados de urea | |
BR112015028871A2 (pt) | novos compostos de 3,4-dihidro-2h-isoquinolina-1-ona e 2,3-dihidro-isoindol-1-ona | |
AR089878A1 (es) | Compuestos fungicidas de pirimidina i | |
AR093168A1 (es) | COMPUESTOS DE OXAZOLIDINONA COMO INHIBIDORES DEL CANAL KCa3.1 | |
BR112015023280A2 (pt) | derivados de dihidroquinolin-2-ona para utilização como inibidores da aldosterona sintase | |
AR089903A1 (es) | Derivados de azetidina | |
AR101616A1 (es) | COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |